ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1749

Fatty Acid Synthase Is a Critical Repressor of Ferroptosis in Rheumatoid Arthritis
Abstract Number: 1750

Dysregulated NUB1 and Neddylation Enhances Rheumatoid Arthritis Fibroblast-Like Synoviocyte Inflammatory Responses
Abstract Number: 1751

Profiling of Anti-PAD IgG and IgA in Patients from the Head-to-head Adalimumab vs Abatacept Rheumatoid Arthritis AMPLE Trial and Matched Healthy Controls
Abstract Number: 1752

Fibroblast Expression of Neurotransmitter Receptor HTR2A Associates with Inflammation in Rheumatoid Arthritis Joint
Abstract Number: 1753

Acylcarnitine Enrichment Is a Characteristic of Rheumatoid Arthritis Fibroblast-Like Synoviocyte Metabolic Fingerprint
Abstract Number: 1754

Novel and Unique Rheumatoid Factors Cross-React with Viral Epitopes in COVID-19
Abstract Number: 1755

Unique Pattern of Cadherin 6 Localization in Fibroblast-Like Synoviocytes
Abstract Number: 1756

Circulating CD4+CD25+CD127-FoxP3+CD39+ T Cells Predict the Response to Methotrexate Across Basal Disease Activity Strata in Early Rheumatoid Arthritis
Abstract Number: 1757

Quantitative Assessment of Synovial Vascularity Using Power Doppler Index in Rheumatoid Arthritis and Psoriatic Arthritis Patients with High Disease Activity
Abstract Number: 1758

Identification of Circulating Autoantibodies Associated with ACPA Status in Early Rheumatoid Arthritis
Abstract Number: 1759

Runx1 Is a Key Transcription Factor That Drives Synovial Fibroblast Pathogenicity in Rheumatoid Arthritis
Abstract Number: 1760

Methotrexate Augments the Release of Granulocyte-macrophage Colony-stimulating Factor from Activated Rheumatoid Arthritis Fibroblast-like Synoviocytes – Possible Consequences for Persistence of Joint Inflammation
Abstract Number: 1761

JAK/STAT Inhibition Modifies the Innate Lymphoid Cells 1 Immune Response in Patients with Rheumatoid Arthritis
Abstract Number: 1762

Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls
Abstract Number: 1763

Asthma Severity Is Associated Increased Serum Anti-cyclic Antibody Level at Baseline and in Increase During Longitudinal Follow-up

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].